Concept-level assumptions require QS, engineering, hospital operator, regulatory, and financial validation before investor release.
Investment and Costing
EUR 5B+ per province, EUR 45B+ national ecosystem program.
Concept-level assumptions require QS, engineering, hospital operator, regulatory, and financial validation before investor release.
Investment and Costing
EUR 5B+ per province, EUR 45B+ national ecosystem program.
Hospital and clinical infrastructure: EUR 1.0B - 1.5B.
Medical equipment, diagnostics, ICU, theatres, pharmacy robotics, and digital hospital systems: EUR 500M - 900M.
University, research, simulation, training, and student/staff facilities: EUR 500M - 800M.
Private medical tourism and hospitality: EUR 400M - 800M.
Community care and outreach: EUR 250M - 500M.
Regenerative medicine, gene therapy, cleanrooms, cell banking, trials, and advanced rehab: EUR 300M - 700M per strategic campus.
Power, water, waste-to-energy, biofuel, gas/pipelines, medical gas, utilities, and resilience: EUR 700M - 1.2B.
Funding: DFIs, sovereign funds, ESG infrastructure funds, private equity, hospital operators, vendor finance, universities, government support, research grants, utilities investors, hospitality/property partners, biotech/pharma partners, green bonds, and provincial SPVs.
Governance
Advanced therapy, costing, and partner claims require evidence before investor release.
Gene therapy is treated as a Tygan-owned or Tygan-controlled patent platform from project start. Medical pathways remain subject to clinical governance, SAHPRA, ethics, POPIA, patient consent, scientific validation, and independent legal review.